Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2018

Is Maintaining a Gluten-Free Diet Effective in
Decreasing Symptoms for Irritable Bowel
Syndrome?
Christina T. Larkin
Philadelphia College of Osteopathic Medicine

Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Medicine and Health Sciences Commons
Recommended Citation
Larkin, Christina T., "Is Maintaining a Gluten-Free Diet Effective in Decreasing Symptoms for Irritable Bowel Syndrome?" (2018).
PCOM Physician Assistant Studies Student Scholarship. 369.
https://digitalcommons.pcom.edu/pa_systematic_reviews/369

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Is Maintaining a Gluten-Free Diet Effective in Decreasing
Symptoms for Irritable Bowel Syndrome?

Christina T. Larkin, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirements For
The Degree of Master of Science
In
Health Sciences – Physician Assistant

Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Suwanee, Georgia

December 15, 2017

ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not a glutenfree diet is effective in decreasing symptoms for irritable bowel syndrome (IBS).
Study Design: Systemic review of three randomized, double-blind, placebo-controlled trials
published between 2010-2016, all in the English language.
Data Sources: Data sources obtained for this review were studies published in peer reviewed
journals found using PubMed Database and were selected based on outcomes measured and
relevance to the objective.
Outcomes Measured: The outcomes measured were based on reduction in abdominal symptoms
in IBS patients. Outcomes were measured by a series of 10 cm Visual Analog Scale (VAS). The
VAS monitored symptoms with 0 representing no symptoms and 10 indicating severe clinical
symptoms. Symptoms observed included abdominal pain, bloating, satisfaction with stool
consistency, and overall well-being. Patients completed a questionnaire on primary outcomes
and symptoms. Significance of outcomes were determined using p-value, relative benefit
increase, absolute benefit increase, and numbers needed to treat.
Results: All three studies showed a significant decrease in abdominal symptoms in IBS patients
following a gluten-free diet. Biesiekierski et al. found a statistically significant decrease in
abdominal symptoms at the end of the 6 weeks study with patients who had the gluten-free diet
compared to the gluten diet (p=0.001). Elli et al. study also found a significant difference in
patients that had the gluten-free diet compared to the gluten diet (p= 0.001). Shahbazkhani et al.
found reduction in abdominal symptoms with a gluten-free diet (p< 0.001).
Conclusions: The randomized controlled trials discussed in this review suggest that a gluten-free
diet is effective in decreasing symptoms for IBS.
Keywords: irritable bowel syndrome, gluten-free diet
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Introduction
Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal
disorders.1,2 IBS is a chronic disorder characterized by abdominal pain with association of
alternating bowel movements.1 It is diagnosed with the Rome III criteria which includes having
abdominal pain with 2 of the 3 criteria: abdominal discomfort relieved with defecation, change in
stool frequency, and change in stool appearance. There are three main subtypes of IBS including
IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M).
Approximately 10-15% of adults and adolescents have symptoms consistent with IBS.1
IBS affects around 11% of the population globally.2 IBS is important to address in
healthcare because approximately 50% of people who experience symptoms from IBS will
consult a healthcare provider.3 Approximately 50% of patients with IBS report their first
symptoms before the age of 35.3 Patients over 50-years-old, often have worst quality of life.3 The
estimated annual cost for IBS treatment is between 1.7 billion dollars and 10 billion dollars in
direct medical costs (medications) and 20 billion dollars in indirect (absentee from work)
medical costs in the United States.4 The exact number of healthcare visits due to IBS within the
past few years are not known; however, it is estimated that between 10% and 70% of patients
visit their primary care provider for IBS symptoms. IBS patients are the largest subgroup seen in
gastroenterology clinics.2
The cause of IBS is not completely understood. The pathogenesis of IBS is thought to be
from altered gastrointestinal motility, brain-gut interactions, bacterial overgrowth, and food
sensitivity.5 The first line methods to treat IBS are reassurance, lifestyle modifications, and
dietary modifications. Pharmacologic treatment can be used to minimize symptoms including
polyethylene glycol or magnesium hydroxide for constipation, loperamide for diarrhea, and
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antispasmodics.1,5,6 Other adjunct treatments for IBS include cognitive behavioral therapy with
antidepressants like tricyclic antidepressants (TCA).5,6
Currently, there are several treatment options and medications that can improve the
symptoms of IBS; however, there is not one single therapy that cures all IBS symptoms. The true
efficacy of having a gluten-free diet is still not highly researched. It is suggested that gluten
causes intestinal injury and/or inflammation in patients with IBS. Gluten is found in three types
of grains including wheat, rye, and barley. Wheat has been found to be one of the most common
factors to induce gastrointestinal symptoms such as abdominal pain. Evidence suggest that
targeted dietary carbohydrates exclusion can provide clinical benefit to patients with IBS.
Therefore, a gluten-free diet is an alternative for relief of symptoms of IBS. A gluten-free diet
has shown to be effective in treatment for IBS by decreasing irritation of the intestines. This
systematic review evaluates three randomized control trials to determine if maintaining a glutenfree diet is effective in decreasing symptoms for IBS.
Objective
The objective is this selective EBM review is to determine if a gluten-free diet is
effective in decreasing symptoms for irritable bowel syndrome (IBS).
Methods
Criteria used for selection of studies for this systemic evidence-based review are focused
on populations, interventions, comparisons, and outcomes measured. The population studied in
these articles were patients with IBS using the Rome III criteria (Table 1). The patients were
greater than 16 years old without any other known gastrointestinal disease including celiac
disease. The intervention was a gluten-free diet compared to a gluten diet. The treatment group
received a gluten diet while the control group received a gluten-free diet. The outcomes that were

Larkin, Irritable Bowel Syndrome and Gluten 3
measured used patient-oriented evidence that matters including improvements of the overall
symptoms of IBS such as bloating, abdominal pain, stool consistency, nausea, tiredness, and
general well-being while on a gluten-free diet verses a non-gluten free diet.
Research for this systematic review was obtained from PubMed that were doubleblinded, randomized controlled trails published in peer-reviewed journals. All studies were
published in the English language and published within the last 15 years. Key words that were
searched in these articles were “irritable bowel syndrome” and “gluten-free diet.” The articles
were selected based on relevance to the clinical questions and outcomes of the studies that
mattered to the patients for this systematic review. The inclusion criteria were adults greater than
16 years old diagnosed with IBS that fulfilled the Rome III criteria (Table 1). The exclusion
criteria were patients who have celiac disease, wheaten allergy, inflammatory bowel disease,
and/or with significant gastrointestinal disease (Table 1). The summary of statistics used by these
studies analyzed the data using p-value, numbers needed to treat (NNT), relative benefit increase
(RBI), and absolute benefit increase (ABI) (Table 2).
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Table 1: Demographics and characteristics of included studies
Study Type
#
Age
Inclusion
Exclusion Criteria
Pts (yrs) Criteria
Biesi- Double- 39
>16
-Age > 16
Patients with celiac
kiersk- blind
years years old
disease, gastrointestinal
7
i
RCT
old
-Symptoms disease, excess alcohol
(2011)
of IBS
intake or intake of nonfulfilling
steroidal antiRome III
inflammatory agents
criteria
-Adherence
of the diet
for at least 6
weeks
8
Elli
Double- 101 > 18 -Age >18
Patients with celiac
(2016) blinded
years years old
disease, wheaten
RCT
old
-Routinely
allergy, inflammatory
attending
bowel diseases,
the
psychiatric disorders,
gastroenter- major abdominal
ological
surgery, diabetes
clinic
mellitus, systemic
-Symptoms autoimmune diseases,
consistent
having gluten-free diet
with Rome
regimen in the past 6
III criteria
months, pregnant or
breast-feeding women,
or already on
pharmacological
therapy
Shahb- Double- 148 > 16 -Age > 16
Patients with celiac
azkha- blinded
years years old
disease, have tried a
9
ni
RCT
old
-Newly
gluten free diet, on a
(2015)
diagnosed
gluten free diet, selfIBS based
exclusion of wheat,
on Rome III inflammatory bowel
criteria
disease and diabetes,
using any drugs for
depression and/or
anxiety, used nonsteroidal antiinflammatory drugs,
with abnormal lab levels

W/D

Interventions

5

Placebo or
gluten diet, in
the form of 2
bread slices
plus one
muffin per day
for 6 weeks,
both groups
were a gluten
free diet

3

Gluten free
diet, placebo or
gluten
ingestion

76

Placebo group
(gluten-free
powder) vs.
gluten
containing
group for 6
weeks, both
groups were on
a gluten-free
diet
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Outcomes Measured
The outcomes measured in these studies were the improvements of the overall symptoms
of IBS while on a gluten-free diet verses a non-gluten free diet. Outcomes collected were patientoriented evidence that matters (POEM). Outcomes were measured using the 10 cm Visual
Analog Scale (VAS). In all studies patients completed a questionnaire, patients were told to rank
their symptoms on a 0 to 10 scale with 0 representing no symptoms and 10 representing the most
severe. Biesikierski et al. measured the outcomes of improvement in symptoms of IBS including
bloating, abdominal pain, stool consistency, nausea, and tiredness. Elli et al. measured the
outcomes by satisfaction of patient’s health status and the severity of symptoms including
abdominal pain, satisfaction with stool consistency, bloating, postprandial fullness and general
well-being. Shahbazkhani et al. measured the outcomes of improvements in symptoms of IBS
including bloating, satisfaction with stool defecation, nausea, fatigue, and overall symptoms.
Results
Three randomized, double-blind trials were selected for this systemic review to determine
the efficacy of a gluten-free diet for treatment of IBS. All three studies, Biesikierski, Elli, and
Shahbazkhani et al. study, utilized dichotomous data based on intention-to-treat analysis. The
analysis of measured outcomes for each study is based on the overall improvement of symptoms
for IBS.
Biesikierski et al. study, used gluten-free diets as the placebo for the control group (n=15)
verses gluten diet as the intervention groups (n=19).7 Changes in symptoms in patients with IBS
were assessed. This study included patients greater than 16 years old, symptoms of IBS, and
adherence of diet for at least 6 weeks. This study excluded patients with celiac disease,
gastrointestinal disease, and excess alcohol intake. Based on the inclusion and exclusion criteria,
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39 patients were included, and 34 patients were able to complete the study with 5 patients who
had withdrawn from the study (Table 1). Patients that ceased the study prematurely stopped due
to intolerable increase in abdominal symptoms. The patients that participated in the study
received either gluten or placebo in the form of two bread slices plus one muffin per day with a
gluten-free diet for up to 6 weeks. Food diaries from the patients were maintained in week 3 and
week 6 of the treatment period. Adherence was measured by food supplements consumption and
maintaining a gluten-free diet. Consumption was 95% and 96% in placebo and gluten groups,
respectively. Patients were asked if at the end of each week if symptoms were adequately
controlled. More patients in the gluten group reported “no” to symptoms well-controlled
compared to the placebo group (p= 0.001) (Table 2). After week 1 therapy, changes in symptoms
from baseline scored on the VAS were significantly different in those who had the gluten diet.
The overall results of the study indicated that patients in the gluten group had a greater score in
severity of pain, bloating, satisfaction with stool consistency, and tiredness. Based on the results
in the Biesikierski et al. study, relative benefit increase (RBI) was -41.1%, absolute benefit
increase (ABI) was -28%, and the numbers needed to treat (NNT) was -3 (Table 2). The negative
ABI indicates that there was 28% increase of an adverse event as a result of the gluten diet. The
negative NNT value means that for every 3 participants who had a gluten containing diet, there
was one fewer incidence of decreased IBS symptoms than in the group of participants in the
placebo group.
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Table 2: Comparison and statistical significance of outcomes measured of included studies
Study
P-Value
RBI
ABI
NNT
Biesikierski7

0.001

-41.1%

-28%

-3

Elli8

0.001

-67.2%

-50.6%

-1

Shahbazkhani9

<0.001

-69.3%

-58.1%

-1

In the Elli et al. study, 140 patients were enrolled, and 134 patients completed the 3-week
gluten-free diet during the first period of the study.8 Out of the 134 patients, 101 patients
responded to a gluten-free diet and 3 patients refused randomization. In phase 2, 98 patients were
randomized for either administration of placebo or gluten with a 7-day crossover. Inclusion
criteria included patients greater than 16 years old and newly diagnosed with IBS based on Rome
III criteria. Exclusion of patients with celiac disease, wheaten allergy, inflammatory bowel
disease, psychiatric disorder, and any major comorbidities due to wanting to focus on a
population group primarily with IBS. In phase 2 of the study, patients were divided into a control
group (n=48) and an interventional group (n=58) where they were administered gluten
supplements. Both groups were administered 7 gastrosoluble capsules per day. Each patient was
administered 5.6 g of gluten content to consume. During phase 1, no adverse events were noted
during the three-week gluten free diet course; however, during phase 2, one adverse event
occurred during the placebo administration. Mild periorbital edema was recorded. The patients
were also asked to report their general wellbeing using the VAS. The double-blind placebocontrolled challenge (DBPCC) positive indicated symptoms when eating a gluten-diet and
DBPCC negative indicated no symptoms when eating a gluten-diet (Table 3). Abdominal pain
was 5.4 ± 2.4 for DBPCC positive and 3.2 ± 2.8 for DBPCC negative.8 Based on the results the
RBI was -67.2%, ABI was -50.6%, and the NNT was -1 (Table 2). The negative ABI indicates
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that there was 50.6% increase of an adverse event as a result of the gluten diet. This negative
NNT value indicates that for every 1 participant who had a gluten containing diet, there was one
fewer incidence of decreased IBS symptoms than in the group of participants in the placebo
group. The p-value is 0.001 which is statistically significant.
Table 3: Double-blind placebo-controlled challenge abdominal symptoms mean and
standard deviation
Variable
Abdominal pain
Stool consistency
satisfaction
Bloating
Postprandial
fullness
Early satiety
Epigastric pain
Other
gastrointestinal
symptoms

DBPCC Positive
5.4 ± 2.4
4.5 ± 2.9

DBPCC Negative
3.2 ± 2.8
5.7 ± 3.0

P-value
0.006
0.08

8.2 ± 2.8
6.6 ± 3.0

3.6 ± 2.9
4.9 ± 2.9

0.0001
0.01

6.4 ± 2.8
2.3 ± 2.3
4.6 ± 4.0

4.4 ± 2.9
3.0 ± 3.0
3.4 ± 3.0

0.03
0.27
0.41

In Shahbazkhani et al. study, 148 patients fulfilled the Rome III criteria and were enrolled
in the study between 2011 and 2013.9 However, only 72 patients met the inclusion and exclusion
criteria and continued with the study (Table 1). Patients included were greater than 18 years old
and had symptoms consistent with IBS. The patients were randomly allocated into two groups: a
placebo group (n=37) that received gluten-free supplements and the interventional group (n=35)
that received gluten supplements. The experimental group that received gluten were given a
packet of 100 grams containing gluten meal. The placebo group received gluten-free powder in
the form of packets with 100 grams containing powder of gluten-free foods. Both groups
consumed the powder for 6 weeks while on a gluten-free diet. Powder packets were to be poured
in a cup of water containing 150 mL of warm water, consumed at breakfast and at dinner.
Weekly follow-up assessment was used to evaluate compliance of gluten-containing diet.
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Optimal dietary compliance was indicated if consumption of gluten was less than 100 mg/day
and those patients (8/80) that did not comply with this policy did not continue with the study.9 In
this trial, there were no adverse events except discomfort or abdominal pain. After the 6 weeks,
the patients in the placebo (the gluten-free) group had more controlled abdominal symptoms then
the gluten-containing group (p< 0.001).9 There was a change in abdominal symptoms by week 1
listed in Table 4. The change in symptoms score was increased from 3.1 ± 2.3 to 5.1 ± 2.2 after
having a gluten diet and was decreased from 8.4 ± 1.5 to 3.1 ± 2.3 while on a gluten-free diet
(Table 4).9 There was also an increase in all symptoms in the gluten-containing group, most
significantly in bloating and overall symptoms (Table 5). Based on the results in the
Shahbazkhani et al. study, RBI was -69.3%, ABI was -58.1%, and the NNT was -1. The negative
NNT value means that for every 1 participant who had a gluten containing diet, there was one
fewer incidence of decreased IBS symptoms than in the group of participants in the placebo
group. Therefore, having a gluten diet had more symptoms then a patient with a gluten-free diet.
The p-value was <0.001 is statistically significant.
Table 4: Mean and standard deviation at week 1
Type of Treatment
Before Use (Mean ±SD)
Gluten
3.1 ± 2.3
Gluten-free
8.4 ± 1.5
SD= Standard Deviation

After Use (Mean ±SD)
5.1 ± 2.2
3.1 ± 2.3

Table 5: Abdominal symptoms with gluten diet vs non-gluten diet
Symptoms
Study Group Overall
Satisfaction with stool Tiredness
symptoms consistency
Gluten74.3%
77.1%
60%
group
Placebo
16.2%
8.1%
8.8%
(Gluten-free)

Nausea

Bloating

8.3%

74.3%

5.4%

16.2%
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Discussion
This systematic review compares three randomized, double-blind, placebo controlled
clinical trials. All three studies, found improvement or reduction in IBS symptoms when having
a gluten-free diet.
Gluten-free diets are used for treatment in not only IBS patients, but also in celiac
patients, other gastrointestinal issues, and personal preference in diet. The availability to
maintain a gluten-free diet is manageable in the United States. Unfortunately, maintaining a
gluten-free diet is not convenient for every patient especially in other countries that have limited
availability to gluten free products. There are no contraindications to maintaining a gluten-free
diet; however, adherence is difficult. Patients would have to avoid all foods containing wheat,
rye, and barley. Patients would also have to avoid hydrolyzed vegetable protein or texturized
vegetable protein due to having fillers with gluten components. Having a gluten-free diet can
lead to deficiencies in fiber and other nutrients. Supplements may be suggested by a provider to
decrease any nutritional deficiencies.
The studies that were discussed in this systematic review contained their own limitations.
In Biesikierski et al., the study population was limited by a small final number (n=34) for sample
size. Recruitment of patients were difficult due to the exclusion criteria of celiac disease. It is
also questionable whether patients that had improvements from the gluten-free diet were
undiagnosed patients with celiac disease. The first line treatment for celiac disease patients are
avoidance of gluten; therefore, those patients would have improvements in symptoms with a
non-gluten diet. There is the possibility that a celiac patient was included in the data. Elli et al.
study limitations included focusing on non-celiac gluten sensitivity (NCGS) patients oppose to
strictly IBS patients, even though the criteria were focused on Rome III criteria. Another
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weakness in the Elli et al. study is determining if the gluten dosage was high enough to activate a
response in the patient. Besides limitations and weaknesses found in these studies, there were
also some limitations in researching studies due to most gluten-free diet studies focused on celiac
disease or NCGS instead of IBS relating to gluten-free diets.
Conclusion
Based on these three randomized, double-blind, placebo controlled clinical trials glutenfree diet is effective in decreasing symptoms for IBS. All three randomized trials, found a
statistically significant improvement in symptoms of IBS including abdominal pain, bloating,
stool defecation, fatigue, and overall symptoms using a gluten-free diet. These studies suggest
incorporating a gluten-free diet in patients with IBS along with other current therapies could be
beneficial in diminishing abdominal symptoms.
Even though with this convincing evidence, additional research should be performed to
determine if efficacy in gluten-free diets have more effect on patients with IBS with constipation
verses IBS with diarrhea verses IBS mixed. Additional research can also test monotherapy of
gluten-free diet compared to dual therapy of gluten-free diet with pharmaceutical therapies to
determine if efficacy is increased with monotherapy verses dual therapy. Lastly, additional
research could determine long-term effects and benefits of having a gluten-free diet.
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